The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc analysis assessed the VE against HZ and postherpeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joon Hyung, Diaz-Decaro, John, Jiang, Ning, Hwang, Shinn-Jang, Choo, Eun Ju, Co, Maribel, Hastie, Andrew, Hui, David Shu Cheong, Irimajiri, Junya, Lee, Jacob, Leung, Edward Man-Fuk, Tang, Haiwen, Tsuru, Tomomi, Watson, Philip, Wu, Zhenhua, Yu, Chong-Jen, Yuan, Yanfei, Zahaf, Toufik, Cunningham, Anthony L., Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189096/
https://www.ncbi.nlm.nih.gov/pubmed/33606577
http://dx.doi.org/10.1080/21645515.2020.1859321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189096/
https://www.ncbi.nlm.nih.gov/pubmed/33606577
http://dx.doi.org/10.1080/21645515.2020.1859321

Ejemplares similares